GRI Bio to Present at Alliance Global Partner's 2024 Healthcare Company Showcase
GRI Bio to Present at Alliance Global Partner's 2024 Healthcare Company Showcase
Live webcast fireside chat on Tuesday, May 21st at 2:40 PM ET
5 月 21 日星期二網絡直播爐邊談話st 美國東部時間下午 2:40
LA JOLLA, CA, May 14, 2024 — GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio, will participate in a fireside chat at the Healthcare Company Showcase hosted by Alliance Global Partners on May 21, 2024 at 2:40 PM ET.
加利福尼亞州拉霍亞，2024年5月14日——GRI Bio, Inc.（納斯達克股票代碼：GRI）（“GRI Bio” 或 “公司”）今天宣佈，該公司正在推進用於治療炎症、纖維化和自身免疫性疾病的自然殺傷性T（NKT）細胞調節劑創新產品線 Marc Hertz，博士，首席執行官 GRI Bio 的，將參加爐邊談話 由聯盟全球合作伙伴主辦的醫療保健公司展示會 美國東部時間 2024 年 5 月 21 日下午 2:40。
A live webcast of the event will be available on the Events page of the Investors section of the Company's website (www.gribio.com).
A 網絡直播 該活動的內容將在 活動 的頁面 投資者 公司網站的部分（www.gribio.com)。
About GRI Bio, Inc.
關於 GRI Bio, Inc.
GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio's therapies are designed to target the activity of NKT cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. iNKT cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio's lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 NKT agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.
GRI Bio是一家臨床階段的生物製藥公司，致力於從根本上改變炎症、纖維化和自身免疫性疾病的治療方式。GRI Bio的療法旨在靶向NKT細胞的活性，NKT細胞是炎症級聯早期的關鍵調節劑，以中斷疾病進展並恢復免疫系統的動態平衡。NKT 細胞是與生俱來的 T 細胞，共有 NK 和 T 細胞的特性，是先天免疫反應和適應性免疫反應之間的功能紐帶。inKT 細胞在傳播炎症和纖維化適應症中觀察到的損傷、炎症反應和纖維化方面起着關鍵作用。GRI Bio的主要項目 GRI-0621 是InKT細胞活性的抑制劑，正在開發爲一種新的口服療法，用於治療特發性肺纖維化，這是一種嚴重的疾病，其需求尚未得到滿足。該公司還在開發用於治療系統性紅斑狼瘡的新型2型NKT激動劑產品線。此外，GRI Bio擁有超過500種專有化合物的庫，有能力爲不斷增長的管道提供燃料。
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
GRI@jtcir.com
投資者聯繫人：
JTC Team, LLC
珍妮·托馬斯
(833) 475-8247
GRI@jtcir.com
譯文內容由第三人軟體翻譯。